Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 328, Issue 2, 1995, Pages 151-161

  Suzuki, Hiroshi ^a   Ikeda, Tomotake ^a   Yamagishi, Takehiro ^a   Nakaike, Shiro ^a   Nakane, Sadao ^a   Ohsawa, Motoyasu ^b  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Chromosomal aberration; Chromosome type aberration; Cleavable complex formation; Topoisomerase inhibitor

Indexed keywords

ACLARUBICIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE;

ANIMAL CELL; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; FIBROBLAST CULTURE; LUNG ALVEOLUS CELL; NONHUMAN; PRIORITY JOURNAL;

2,4-DINITROPHENOL; ACLARUBICIN; ADENOSINE TRIPHOSPHATE; ANIMAL; CAMPTOTHECIN; CELLS, CULTURED; CHROMOSOME ABERRATIONS; DINITROPHENOLS; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; ETOPOSIDE; FIBROBLASTS; HAMSTERS;

EID: 0028954122     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/0027-5107(95)00005-4     Document Type: Article

References (35)

1. The production of chromosomal aberrations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA
2. Mechanisms of chromosomal aberrations production III. Chemicals and ionizing radiation
3. Chapter 24. DNA topoisomerases as therapeutic targets in cancer chemotherapy
4. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme
5. Phase I study of the camptothecin analog CPT-11, using a weekly schedule
6. Altered catalytic activity of and DNA cleavage by DNA topisomerase II from human leukemic cells selected for resistance to VM-26
7. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide
8. Cytogenetical characterization of Chinese hamster ovary X-ray-sensitive mutant cells, xrs5 and xrs6 IV. Study of chromosomal aberrations and sister-chromatid exchanges by restriction endonucleases and inhibitor of DNA topoisomerase II
9. Phase I and pharmacokinetic trial of continuous infusion topotecan in patients with refractory solid tumors
10. Biochemical lesions in DNA associated with the antiproliferative effects of mitoxantrone in the hepatoma cell
11. Human peripheral blood lympocytes for the analysis of chromosome aberrations in mutagen tests
12. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone
13. Hypersensitivity of cultured ataxia-telangiectasia cells to etoposide
14. Chromosome tests with 134 compounds on Chinese hamster cells in vitro. A screening for chemical carcinogens
15. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
16. A new cell line derived from newborn Chinese hamster lung tissue
17. Involvement of intracellular ATP in cytotoxicity of topoisomerase II-targeting antitumor drugs
18. Firefly luciferase assay for ATP production by mitochondria
19. Mechanism of action of antitumor drug etoposide: a review
20. Single-strand DNA cleavages by eukaryotic topoisomerase II
21. Eukaryotic topoisomerase II. Characterization of enzyme turnover
22. Catalytic function of DNA topoisomerase II
23. The biological activity of hydrogen peroxide I. Induction of chromosome-type aberrations susceptible to inhibition by scavengers of hydroxyl radicals in human embryonic fibroblasts
24. Mechanism of induction of chromosome aberrations by inhibitors of DNA topoisomerases
25. Mechanisms of induction of specific chromosomal alterations
26. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II
27. DNA strand scission induced by adriamycin and aclacinomycin A
28. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: Role of topoisomerase I
29. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats
30. Determination of ATP in Chlorella with the luciferin-luciferase enzyme system
31. Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells
32. DNA topoisomerase-targeting antitumor agents and drug resistance
33. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
34. Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure-activity relationships of marcellomycin and its analogues as compared to adriamycin
35. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus